Pharma Equity Group A/S Financials
PEG.XCSE
All currency values in kr millions unless otherwise noted
Scroll
| Income Statement | DEC 2025 | DEC 2024 | DEC 2023 | DEC 2022 | DEC 2021 |
|---|---|---|---|---|---|
| Revenues | |||||
| Revenue | kr 0 | kr 0 | kr 0 | kr 0 | kr 0 |
| Cost of Revenue | kr 0 | kr 0 | kr 0 | kr 0 | – |
| Gross Profit | kr 0 | kr 0 | kr 0 | kr 0 | – |
| General & Administrative | kr 12 | kr 12 | – | – | – |
| Research & Development | kr 5 | kr 9 | – | – | – |
| Total Operating Expenses | kr 17 | kr 21 | kr 25 | kr 11 | – |
| Operating Income | -kr 17 | -kr 21 | -kr 25 | -kr 11 | kr 0 |
| Non-Operating | |||||
| Net Interest Expense | -kr 3 | -kr 5 | -kr 2 | -kr 0 | -kr 1 |
| Other Non-Operating Income (Expense) | -kr 7 | -kr 16 | – | – | – |
| EBT (Earnings Before Tax) | -kr 26 | -kr 42 | – | – | – |
| Income Tax Expense | -kr 1 | -kr 2 | -kr 2 | -kr 2 | kr 0 |
| Earnings from Continuing Ops | -kr 25 | -kr 41 | – | – | – |
| Net Income | |||||
| Net Income | -kr 25 | -kr 41 | -kr 24 | -kr 9 | kr 5 |
| Per Share Data | |||||
| Revenue Per Share | kr 0.00 | kr 0.00 | kr 0.00 | kr 0.00 | kr 0.00 |
| EPS (Basic) | -kr 0.02 | -kr 0.02 | -kr 0.02 | -kr 0.01 | kr 0.10 |
| EPS (Diluted) | -kr 0.02 | -kr 0.02 | -kr 0.02 | -kr 0.01 | kr 0.10 |
| Shares Outstanding | 1.27B | 2.03B | 1.22B | 944.4M | 56.8M |
Pharma Equity Group A/S (PEG.XCSE) financials: revenue, profit and margins
Pharma Equity Group A/S (PEG.XCSE) generated about DKK 0.00 in revenue and -DKK 25 million in net income over the trailing twelve months. Figures are from company filings; this is analysis, not investment advice.
Frequently asked
What is Pharma Equity Group A/S's (PEG.XCSE) revenue?+
Pharma Equity Group A/S generated about DKK 0.00 in revenue over the trailing twelve months. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.
Is Pharma Equity Group A/S profitable?+
Pharma Equity Group A/S reported about -DKK 25 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
Peers
Biotechnology · Pick stocks to compare with PEG.XCSE
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing PEG.XCSE
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.